Skip to content
thestock.space

As of 6 Nov 2026, Laurus Labs trades at 94.4× trailing earnings, above the industry P/E of 28.7×. Its ROCE of 20% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 3.8% and 4.0% a year over 3 years. Its dividend yield is 0.1%, and debt is 0.42× equity. It is a large-cap company with a market cap of ₹1.3 lakh crore, ranked 4th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 139% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹2,329.70
Day high
₹2,341.50
Day low
₹2,309.10
Prev. close
₹2,346.00
Volume
14.5 L

Health check

2 good · 1 fair · 3 to check
  • ReturnsAhead

    +138.6% over a year, better than 7 of 7 peers.

  • Price tagPricier

    P/E 94.4 vs industry 28.7.

  • GrowthSlow

    Sales +3.8%, profit +4.0% a year over 3 years.

  • ProfitabilityAverage

    ROCE 19.5% vs peer median 14.9%.

  • Balance sheetSolid

    Debt 0.42× equity, interest covered 8.3×, Piotroski 8 of 9.

  • Red flags1 to check

    P/E of 94.4 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Large cap

₹1.3L Cr, #4 of 154 in its industry by size.

Defensive

Beta 0.22 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹7,823 Cr · profit ₹1,340 Cr
Market cap
₹1.3L Cr
Large cap
P/E
94.4
Industry 28.7
Price to book
20.86
Peers 4.99
Dividend yield
0.09%
ROE
24.0%
Peers 13.6%
ROCE
19.5%
Peers 14.9%
Debt to equity
0.42
Debt ₹2,625 Cr
EPS (TTM)
₹24.78
Face value ₹2
OPM (TTM)
30.4%
Net margin 17.1%
Sales growth
+33.4%
Latest quarter vs a year ago
Profit growth
+126.0%
Latest quarter vs a year ago
Price to sales
16.16
EV/EBITDA 54.2

Strengths and risks

Strengths

  • Return on equity of 24.0%.
  • Quarterly profit up 126.0% on a year ago.
  • Quarterly sales up 33.4% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • P/E of 94.4 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media…

Headquarters
Hyderabad
Employees
7,059
Sector
Healthcare
ISIN
INE947Q01028
Website
lauruslabs.com

Price range

52 weeks

₹917.95₹2,441.90

Today

₹2,309.10₹2,341.50
Avg volume (3M)
24.5 L
1-year return
plus 138.6%
From 52-week high
minus 4.2%

Analyst consensus

14 analysts
HoldMean target ₹2,156.29 minus 7.9%

The mean target is below today’s price.

Target range, with today’s price

Low ₹900.00High ₹2,830.00

Next results expected around 22 Jan 2027

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.87%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.30%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.81%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.59%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.93%minus 6.6%
MANKINDMankind Pharma2,540.00plus 0.87%1,04,91346.85.9713.7%13.6%26.5%17.7%14.3%0.00%plus 6.3%
Median of 7 peers–0.85%1,19,49140.94.9914.9%13.6%26.5%11.0%12.1%0.59%13.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
1,5701,7781,8122,0262,206
1,1871,2981,2991,3881,456
382480512638750
24.3%27.0%28.3%31.5%34.0%
10.45.811.89.213
51.538.840.442.244.1
117121122124127
224327361481592
28.2%22.5%22.0%24.8%26.2%
163252279368441
3.024.655.176.808.16

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+3.8%
Profit CAGR 3Y
+4.0%
EPS CAGR 3Y
+4.0%
ROE
24.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
6,0145,0025,5086,721
–minus 16.8%+10.1%+22.0%
4,3964,2224,4534,935
1,6187791,0551,786
26.9%15.6%19.2%26.6%
−62.6−1.98.743.6
123172207161
324385430480
0.215.157.1−7
1,1092364841,182
28.2%28.8%26.8%24.7%
790161358889
–minus 79.7%+123.2%+148.0%
14.642.976.6416.45

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
108108108108
3,9304,0034,3655,192
2,0152,5772,7642,518
1,6081,6992,0992,693
7,6608,3879,33610,511
3,7004,0484,3164,879
551423458773
3.53.43.421.1
45.713999.5113
3,3603,7744,4584,725
7,6608,3879,33610,511

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
9946666021,624
−996−822−682−1,089
−26.625039.3−525
−28.893.1−40.810.1
−990−678−641−1,070
3.7−12.6−39.4554
−107−86.2−43.1−86.3

Shareholding pattern

Source: NSE filings
27.5%
promoters
  • Promoters27.47%
  • Public72.53%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202627.47%72.53%0.00
30 Jun 202627.47%72.53%minus 0.02
31 Mar 202627.49%72.51%0.00
31 Dec 202527.49%72.51%minus 0.10
30 Sep 202527.59%72.41%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you